Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports.
Saudi Pharm J
; 30(8): 1193-1199, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-36164566
ACS, Acute Coronary Syndrome'; ADRs, Adverse Drug Reactions; ATE, Arterial Thromboembolism; Acute coronary syndrome; Checkpoints inhibitors; DVT, Deep Vein Thrombosis'; Deep vein thrombosis; IC, Information Component; ICIs, Immune Checkpoint Inhibitors; ICSRs, Individual Case Safety Reports; IQR, Interquartile Range; LMWH, Low-Molecular-Weight Heparin; MI, Myocardial Infarction; MedDRA, Medical Dictionary For Regulatory Activities; PD-1, Programmed Cell Death-1; PD-L1, Programmed Cell Death Ligand 1; PE, Pulmonary Embolism'; PT, Preferred Term; Pulmonary embolism; RR, Risk Ratio; TTO, Time To Onset; UFH, Unfractionated Heparin; UMC, Uppsala Monitoring Centre; VTE, Venous Thromboembolism; VigiBase; WHO, World Health Organization; irAEs, Immune-Related Adverse Events
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article